CHM.CN stock jumped 900.00% to C$0.05 on 06 Mar 2026 during Canadian market hours on the CNQ exchange, up from a previous close of C$0.005. The move made Waverunner Capital Inc. a high-volume mover on our radar despite unclear intraday volume prints. We examine valuation, liquidity, sector context and short-term forecasts to help traders parse this rapid swing.

Intraday move and trading context for CHM.CN stock

The intraday print shows C$0.05 as both the day low and day high, matching a reported change of +C$0.045 (900.00%). The stock’s 50-day average is C$0.042 and 200-day average is C$0.048, signalling a move back toward longer-term averages. Year range sits at C$0.05–C$0.10, and reported average daily volume is 28,908.00 shares, underscoring thin liquidity that can amplify price swings.

Financial snapshot and valuation for CHM.CN stock

Waverunner Capital Inc. shows modest scale with a market cap of CAD 37,211,650.00 and 744,233,000 shares outstanding. Reported EPS is -0.01 and the trailing PE is -5.00, reflecting a loss-making status. Cash per share is 0.008, book value per share is -0.142, and current ratio is 0.10, which highlights a stretched short-term balance sheet relative to the Healthcare sector average current ratio near 1.90.

Meyka AI rates CHM.CN with a score out of 100 and analyst view

Meyka AI rates CHM.CN with a score out of 100: 64.98 (Grade B, SUGGESTION: HOLD). This grade factors S&P 500 and sector comparisons, industry metrics, financial growth, key ratios and analyst consensus. The grade reflects small market cap, negative earnings and sector headwinds while recognising potential upside from venture investments. These grades are not guaranteed and are informational only.

Technical signals and liquidity risks in CHM.CN stock

Technical context is dominated by very low liquidity and wide bid/ask risk. Average volume 28,908.00 versus unclear intraday prints creates execution risk for size. Price sits slightly above the 50-day average, but spreads and potential stale bids can produce volatile one-day moves. For active traders, limit orders and size discipline are essential.

Meyka AI’s forecast model projects CHM.CN stock targets and scenarios

Meyka AI’s forecast model projects a near-term base case of C$0.08 (implied upside 60.00% vs C$0.05), a bullish scenario of C$0.12 (implied upside 140.00%), and a downside scenario of C$0.03 (implied downside -40.00%). Forecasts are model-based projections and not guarantees. These scenarios assume no major financing dilution or corporate news that would materially change enterprise value.

What catalysts and data to watch for CHM.CN stock

Key monitors include regulatory filings, any financing or PIPE notices, insider transactions and news on venture holdings in renewables or biotech. Waverunner changed its name in June 2024 from Chemistree Technology and has limited recent earnings cadence; the last earnings announcement listed is 2023-03-31. Use the company site for filings and background: Waverunner website. For an official symbol image and profile use: Company profile image.

Final Thoughts

CHM.CN stock’s intraday 900.00% jump to C$0.05 on 06 Mar 2026 highlights the stock’s extreme volatility and thin liquidity on the CNQ exchange. Fundamentals show a small market cap (CAD 37,211,650.00), negative EPS (-0.01) and stretched current ratio (0.10), which together raise financing and execution risks. Meyka AI’s forecast model projects a base target of C$0.08 (about 60.00% implied upside from today’s price) while flagging a downside case to C$0.03 if dilution or sell-side pressure appears. Traders drawn to CHM.CN stock should prioritise order size, confirm real-time volume prints, and monitor corporate filings for financing updates. Meyka AI, an AI-powered market analysis platform, provides these model-based projections as one input among many; forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.